Open Access

The value of correlation of serum 20S proteasome concentration and percentage of lymphocytic apoptosis in critically ill patients: a prospective observational study

Critical Care201014:R215

https://doi.org/10.1186/cc9340

Received: 10 January 2010

Accepted: 25 November 2010

Published: 25 November 2010

Abstract

Introduction

Sepsis in critically ill patients is almost associated with bad prognosis and its early detection may improve the prognosis. However, it is difficult to monitor the immunological state of these patients depending on the traditional markers of infection or inflammatory mediators. Accelerated lymphocyte death may reflect good idea about the prognosis especially when combined with 20S proteasome determinations, a recently discovered marker for muscle degradation in patients with sepsis. The hypothesis of the present study is to evaluate the role of serum 20S proteasome at early diagnosis of sepsis and its correlation with lymphocyte apoptosis to predict prognosis and consequently the early interference in critically ill patients suffering from a broad range of diseases in the intensive care unit.

Methods

Sixty-seven critically ill adult intensive care patients were divided into two groups, 32 septic critically ill patients (sepsis group) and 35 non-septic critically ill patients (non-sepsis group), in addition to 33 apparently healthy subjects from the out patient clinic (control group). Patients were tested for serum values of 20S proteasome using ELISA and for percentage of lymphocyte death using annexin V and 7-aminoactinomycin D dye by flow cytometry.

Results

Measured median value of serum 20S proteasome was significantly higher in septic patients compared with both the non-septic and control groups. A significant increase in the percentage of apoptotic lymphocytes was detected in septic patients when compared with the non-sepsis and control groups. The correlation of both 20S proteasome and percentage of apoptotic lymphocytes was found to be significantly positive in both septic and non-septic patients.

Conclusions

The correlation of median values of 20S proteasome and the percentage of apoptotic lymphocyte median values could be a good indicator of patient prognosis and survival in critically ill patients.

Introduction

Sepsis in critically ill patients correlates with bad prognosis. Previous studies have tried to monitor biomarkers for the detection of sepsis, however none of these markers provided a good idea about the immunologic state of the patients, thus, the need for immunologic markers for early detection of an immunocompromised state in critically ill patients is essential [1].

Increased lymphocyte apoptosis is one of the suggested causes of immunosuppression in critically ill patients. In the presence of a hyperinflammatory state, apoptosis may be beneficial to the host by eliminating lymphocytes that produce excessive pro-inflammatory cytokines. Conversely, lymphocyte apoptosis could be harmful in sepsis by causing depletion of lymphocytes that are essential for defense against invading microorganisms [2].

Muscle cachexia and degradation of myofibrillar proteins is another common important clinical feature in critically ill septic patients [3]. Recently, a study in patients with sepsis confirmed that muscle catabolism in patients with sepsis is associated with upregulated energy-ubiquitin-dependent protein breakdown [4]. In this proteolytic pathway, proteins are conjugated to ubiquitin, then they are degraded by the 26S proteolytic complex [5], which is composed of a core known as 20S proteasome which is composed of seven different α and β subunits arranged in four heptameric rings [6]. Increased level of circulating 20S proteasome was proposed as a marker of cell damage and protein breakdown in critically ill septic patients. The study hypothesis is to determine the role of serum 20S proteasome at early diagnosis of sepsis and its correlation with lymphocyte apoptosis to predict prognosis and early interference in critically ill patients suffering from a broad range of diseases in the intensive care unit (ICU).

Materials and methods

After the study approval by an Investigational Review Board of the Faculty of Medicine, Tanta University, an informed consent was obtained from all patients who were able to grant such consent prospectively; otherwise, consent was obtained retrospectively or from the patient's next-of-kin. The study was conducted over one year in the ICU of the Emergency Hospital of Tanta University, Tanta, Egypt. It is 25-bed medical/surgical ICU.

Sixty-seven critically ill adult intensive care patients divided into two groups, 32 septic patients (sepsis group) and 35 nonseptic critically ill patients (nonsepsis group), and 33 apparently healthy subjects from the outpatient clinic (control group) were observed regarding 20S proteasome and the percentage of lymphocyte apoptosis. Patients who received corticosteroids or anti-inflammatory drugs before admission, who had immunosuppressive illness, who had chronic organ failure, who received massive blood transfusion, who received radiation therapy or who had previous organ transplantation were excluded from the study. At admission, the patient's age, sex, height and weight were measured. Patients' data include clinical status, Sequential Organ Failure Assessment (SOFA) score, blood pressure, heart rate, respiratory rate, temperature, central venous pressure, laboratory analysis (complete blood count, serum sodium, potassium, calcium, blood urea nitrogen, blood sugar, prothrombin time, aspartate aminotransferase, alanine aminotransferase, albumin and C-reactive protein, and arterial blood gas analysis were recorded. Routine cultures of urine, blood and suspected areas were obtained to determine the presence of infection. We attempted to maintain the patient central venous pressure at 8 to 12 cmH2O and the hemoglobin level at 10 to 12 g/dl. Whenever needed, intravascular fluid replacement, blood products, vasopressor and/or inotropic agents were administered. The physician in the ICU evaluated all of the study patients daily for sepsis, severe sepsis, or septic shock.

The signs of sepsis were body temperature <33.6°C or >38.3°C, tachycardia (>90 beats/minute), ventilatory frequency >20 breath/minute or pressure of carbon dioxide <32 mmHg (unless the patient was mechanically ventilated), a white cell count ≥12 × 109/l or <4 × 109/l, or >10% immature neutrophils, in addition to the presence of infection [7]. Severe sepsis was considered as sepsis with evidence of organ dysfunction and hypoperfusion, acute alteration of mental status, elevated plasma lactate, unexplained metabolic acidosis (arterial pH <7.3), hypoxemia, a decrease in platelet count >50% or ≤100 × 109l/l or prolonged prothrombin time, oliguria and hypotension defined as systolic arterial pressure <90 mmHg or a decrease >40 mmHg. Septic shock was considered as hypotension (<90/60 mmHg) in addition to sepsis syndrome persisting despite adequate fluid resuscitation and requiring intropic support. SOFA score consists of scores from six organ systems (respiratory, cardiovascular, hepatic, coagulation, renal, and neurological) graded from 0 to 4 according to the degree of dysfunction/failure. The aggregate score (total maximum SOFA score) is calculated summing the worst scores for each of the organ systems during the ICU stay [8].

Estimation of 20S proteasome

Microtitration plates coated with monoclonal antibody to 20S proteasome were used. Human sera samples diluted 1:20 were applied to each well for 3 hours at room temperature. A standard curve was established using 20S proteasome standard preparation having concentrations of 5,000 ng/ml to 78 ng/ml (six linear dilution steps). After a washing step, a polyclonal antibody to 20S proteasome α and β subunits was added for 2 hours, followed by another washing step. Peroxidase-conjugated anti-rabbit IgG was used for detection of the antigen, incubated for 1 hour, substrate was added (tetramethyl benzidine) and finally the reaction was stopped with sulfuric acid. Optical density values were determined at 450 nm.

A negative control in the form of bovine serum albumin was used to exclude nonspecific reaction to proteins and no reaction was detected. A positive control in the form of human placental proteasome preparation was also used (AFFINTI Research Products Ltd, Mam Head, Exeter, UK).

Estimation of the percentage of apoptotic lymphocytes by flow cytometry

Whole blood on ethylenediamine tetraacetic acid vacutainer samples were used. Red blood cells were lysed with ammonium chloride 1.0 mM and white blood cells were washed three times with PBS. Cells were incubated for 30 minutes in the dark with the monoclonal antibody for the target CD cells or with the dyes used (annexin V and 7-aminoactinomycin D (7-AAD); Becton Dickinson and Pharmingen (St. Jose, California, USA)). Forward and side scatter properties for lymphocytes were used with the use of a pan-lymphocyte, B-lymphocyte and T-lymphocyte panel including CD19 labeled with cy 5 dye for B cells and CD3 labeled with PerCP dye for T cells. With the use of annexin V labeled with fluorescein isothiocyanate (FITC) and 7-AAD labeled with phycoerythrin staining for apoptotic lymphocytes, the percentage of these cells was detected. Detection of apoptosis using annexin V was accompanied with the use of 7-AAD detection kits. The final combination used for all patients was (CD19/annexin V/CD3/7-AAD).

FITC annexin V staining precedes the loss of membrane integrity that accompanies the latest stages of cell death either due to apoptotic or necrotic processes. Staining with FITC annexin V is therefore typically used with a vital dye such as 7-AAD to identify the early apoptotic cells (phycoerythrin 7-AAD-negative/FITC annexin V-positive) and to differentiate the late apoptotic or dead cells (positive for both 7-AAD and annexin V) from viable cells that are negative for both 7-AAD and annexin V [911].

Results

A total of 100 patients (59 men and 41 women) were included in the study. Thirty-two patients developed septic complications during the ICU stay (sepsis group), 10 patients developed septic shock, 15 patients developed severe sepsis, and 7 patients developed sepsis without any organ dysfunction. Thirty-five patients were critically ill without evidence of infectious organism (non-sepsis group), 10 patients developing non-septic complications in the form of disturbed hepatic or renal functions, electrolyte imbalance or acid-base disorders, in addition to thirty three non-critically ill non-septic patients (control group). No significant difference was detected among the groups except for SOFA score at ICU admission and the duration of the stay in the ICU, which were higher in septic patients (Table 1).
Table 1

Patient characteristics

 

Sepsis group (n= 32)

Non-sepsis group (n= 35)

Control group (n= 33)

Age (years)

44 ± 9.5

45 ± 8.7

44 ± 10.2

Sex ratio (male/female)

19/13

21/14

19/14

SOFA score

12 (7-14)*

6 (3-10)

 

Duration of ICU stay (days)

16.9 ± 4.6*

5.8 ± 2.7

 

Diagnosis

   

Respiratory insufficiency due to:

   

   Bacterial infection

6

  

   ARDS

4

  

   COPD

 

2

 

   Bronchial asthma

 

4

 

   Pulmonary edema

 

3

 

Polytrauma

7

8

 

Orthopedic surgery

9

11

 

Thoracic surgery

6

7

 

Data presented as mean and standard deviation or (interquartile range for SOFA). *Significant change, P < 0.05. ARDS, adult respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment.

There was a significant variation among median values of 20S proteasome in the studied groups: a median value of 25,125 ng/ml in the sepsis group, a median value of 4,560 ng/ml in the nonsepsis group, and a median value of 2,740 ng/ml in the control group. The mean rank was 83.69, 42.66 and 26.64 for the studied group, respectively. The sepsis group showed the highest values, followed by the nonsepsis group and lastly the control group (P < 0.001) (Table 2 and Figure 1).
Table 2

Comparison of the concentration of 20 S proteasome in the studied groups

 

20 S proteasome

 

Range

Median

Mean rank

Sepsis group

13,700 to 38450

25,125.00

83.69

Non-sepsis group

1,170 to 21710

4,590.00

42.66

Control group

1,130 to 4970

2,470.00

26.64

Kruskal-Wallis test

χ2 = 66.764

P = 0.000*

 

Mann-Whitney test

Sepsis and nonsepsis groups

Sepsis and control groups

Nonsepsis and control groups

P value

<0.001*

<0.001*

0.001*

*Significant change, P < 0.05.

Figure 1

Comparison between concentrations of 20 S proteasome in the studied groups.

There was a significant variation of the median values among the studied groups regarding the percentage of apoptotic lymphocytes: the median value for the sepsis group was 11.75%, the median value for the non-sepsis group was 3.6%, while the median value for the control group was 2.2%. The median rank for the studied groups was 84.34, 41.9 and 26.8, respectively. The sepsis group showed the highest values, followed by the non-sepsis group and lastly the control group (Table 3 and Figure 2).
Table 3

Percentage of total apoptotic lymphocytes among the studied groups

 

Range

Median

Mean rank

Sepsis group

8.200 to 18.400

11.750

84.344

Non-sepsis group

1.500 to 9.600

3.600

41.971

Control group

1.300 to 6.400

2.200

27.176

Kruskal-Wallis test

χ2 = 68.506

P = 0.000*

 

Mann-Whitney test

Sepsis and non-sepsis groups

Sepsis and control groups

Non-sepsis and control groups

   Z

-6.917

-6.982

-3.057

   P value

0.000*

0.000*

0.002*

*Significant change, P < 0.05.

Figure 2

Comparison of percentage of apoptotic lymphocytes in the studied groups.

A significant variation of the percentage of apoptotic B lymphocytes was observed in the studied groups: in the sepsis group the median value was 5.9% and the median rank 84.15, while this was 1.8% with a median rank of 41.1 in the non-septic group, and the median value in the control group was 1.09% with a median rank of 28.2 (P = 0.008). Similarly, a significant variation of the percentage of apoptotic T lymphocytes was observed in the studied groups: in the sepsis group the median value was 5.9% and the median rank 83.1, while this was 1.7% with a median rank of 43.4 in the non-septic group, and the median value in the control group was 2.2% with a median rank of 27.1 (P = 0.001) (Tables 4 and 5, and Figures 3 and 4).
Table 4

Percentage of apoptotic B lymphocytes among the studied groups

 

Range

Median

Mean rank

Sepsis group

3.762 to 9.384

5.942

84.156

Non-sepsis group

0.525 to 4.800

1.836

41.118

Control group

0.663 to 4.425

1.097

28.206

Kruskal-Wallis test

χ2 = 66.721

P = 0.000*

 

Mann-Whitney test

Sepsis and non-sepsis groups

Sepsis and control groups

Non-sepsis and control groups

   Z

-6.878

-6.942

-2.663

   P value

0.000*

0.000*

0.008*

*Significant change, P < 0.05.

Table 5

Percentage of apoptotic T lymphocytes among the studied groups

 

Range

Median

Mean rank

Sepsis group

2.375 to 9.016

5.914

83.156

Non-sepsis group

0.735 to 5.785

1.738

43.412

Control group

0.637 to 3.190

1.054

26.853

Kruskal-Wallis test

χ2 = 65.184

P = 0.000*

 

Mann-Whitney test

Sepsis and non-sepsis groups

Sepsis and control groups

Non-sepsis and control groups

   Z

-6.480

-6.929

-3.240

   P value

0.000*

0.000*

0.001*

*Significant change, P < 0.05.

Figure 3

Percentage of apoptotic B lymphocytes among the studied groups.

Figure 4

Percentage of apoptotic T lymphocytes among the studied groups.

Concerning the survival rate for the sepsis and nonsepsis groups, in the sepsis group 21 patients recovered and 11 patients died during the ICU stay compared with 22 patients recovering and 13 patients dying during the ICU stay in the nonsepsis group. There was no significant variation between the two groups concerning the survival rate (Table 6 and Figure 5).
Table 6

Survival rates among the sepsis and non-sepsis groups

  

Survival

  

Alive

Died

Total

Sepsis group

n

21

11

32

 

%

65.63

34.38

100.00

Non-sepsis group

n

22

13

35

 

%

62.86

37.14

100.00

Total

n

43

24

67

 

%

64.18

35.82

100.00

Chi-square test

χ2

0.056

  
 

P value

0.813

  
Figure 5

Survival rate between the sepsis and non-sepsis groups.

Concerning the relation of survival to the concentration of 20S proteasome in the sepsis group, survived patients had a median value of 26,150 ng/ml compared with 19,200 ng/ml in patients who did not survive. The relation of survival to the percentage of apoptotic lymphocytes in the sepsis group, the median value of survived patients was 12.2% compared to 10.5% in non-survived patients. Regarding non-sepsis group, the median value for serum 20S proteasome for survived patients was 4,910 ng/ml while for non-survived patients it was 4,170 ng/ml. Regarding the relation of survival and percentage of apoptotic lymphocytes, the median value of for those who survived was 3.8%, while for non-survived patients it was 3.3%. There was no significant correlation for 20S proteasome and the percentage of apoptotic lymphocytes to the survival rate in both groups separately. A significant positive correlation between the two measured factors 20S proteasome and apoptotic total lymphocytes, B lymphocytes and T lymphocytes in both the sepsis and non-sepsis groups was detected (Tables 7 to 9, and Figures 6 to 11).
Table 7

Correlation of survival and 20 S proteasome in the sepsis and non-sepsis groups

20 S proteasome

Alive

Died

Mann-Whitney test

 

Range

Median

Mean rank

Range

Median

Mean rank

Z

P value

Sepsis group

14,200.00 - 38,450.00

26,150.00

17.69

13,700.00 - 38,200.00

19200.00

14.23

0.992

0.327

Non-sepsis group

1,170.00 - 21,710.00

4,910.00

18.64

12,20.00 - 13,590.00

4170.00

16.92

0.478

0.649

Table 8

Correlation of survival and percentage of total apoptotic lymphocytes in the sepsis and non-sepsis groups

Percentage of apoptotic lymphocytes

Alive

Died

Mann-Whitney test

 

Range

Median

Mean rank

Range

Median

Mean rank

Z

P value

Sepsis group

9.40 to 18.40

12.20

18.12

8.20 to 15.90

10.50

13.41

1.350

0.180

Nonsepsis group

1.50 to 9.60

3.80

18.80

1.80 to 7.40

3.30

16.65

0.598

0.555

Table 9

Correlation between 20 S proteasome and percentage of apoptotic lymphocytes in the studied groups

  

R value

P value

Sepsis group

Apoptotic (total)

0.746

0.000*

 

Apoptotic (B lymphocytes)

0.642

0.000*

 

Apoptotic (T lymphocytes)

0.636

0.000*

Nonsepsis group

Apoptotic (total)

0.768

0.000*

 

Apoptotic (B lymphocytes)

0.636

0.000*

 

Apoptotic (T lymphocytes)

0.766

0.000*

*Significant change, P < 0.05.

Figure 6

Correlation between 20 S proteasome and the percentage of apoptotic total lymphocytes in the sepsis group.

Figure 7

Correlation between 20 S proteasome and the percentage of apoptotic B lymphocytes in the sepsis group.

Figure 8

Correlation between 20 S proteasome and the percentage of apoptotic T lymphocytes in the sepsis group.

Figure 9

Correlation between 20 S proteasome and the percentage of apoptotic total lymphocytes in the non-sepsis group.

Figure 10

Correlation between 20 S proteasome and the percentage of apoptotic B lymphocytes in the non-sepsis group.

Figure 11

Correlation between 20 S proteasome and the percentage of apoptotic T lymphocytes in the non-sepsis group.

Discussion

Critically ill patients, whether suffering from sepsis or not are classified as high-risk patients as regard morbidity and mortality. Previous studies have become growing up to evaluate the immunological state in different diseases, in addition different immunologic markers were previously measured separately to evaluate these patients. In the present study, we tried to evaluate two immunological factors as diagnostic and prognostic markers separately and as both of them together to determine their correlation.

The present study monitored serum levels of 20S proteasome, it was increased in both septic and non-septic critically ill patients compared to healthy controls, with a statistically significant increase in septic patients compared with non-septic patients. The median level in the septic group was 11-fold higher than the control group, while in the non-septic group it was 2 fold higher than in the control group. In their studies, Roth and colleagues and Dutaud and colleagues demonstrated elevated serum 20S proteasome in both septic and control groups, which was 2,157 ± 273 ng/ml and 2,319 ± 237 ng/ml, respectively [12, 13]. Other studies revealed that elevated 20S proteasome usually occurs in variable conditions demonstrating cellular damage and catabolic activity, such as sepsis, trauma and muscle proteolysis, this is explained by the rapidity of the cellular degradation occurring in these conditions [14]. Elevated 20S proteasome was also noticed in variable autoimmune disorders such as systemic lupus and rheumatoid arthritis, and this elevation was closely related to the periods of disease activity. [15]

The activation of both B lymphocytes and T lymphocytes occurring in sepsis usually leads to formation of aberrantly reactive B lymphocytes and T lymphocytes causing an immunodeficient state in those septic patients [16, 17]. Hotchkiss et al., [1] and Bourboulis et al., [18] demonstrated a statistically significant increase in the percentage of dead lymphocytes in septic patients infected with Gram-negative bacteria in comparison to the control group. Baize et al., [19] demonstrated similar increase in the percentage of dead lymphocytes in patients suffering from sepsis.

The present study revealed that either 20S proteasome or the percentage of dead lymphocytes had not any significant correlation separately to the prognosis in both septic and non-septic critically ill patients, while correlation of both 20S proteasome or the percentage of dead lymphocytes was found to have moderate positive correlation in both sepsis and non-sepsis groups.

Previous studies reported increased lymphocyte death (apoptosis) as an evident finding in critically ill septic patients, which was related to the status of humoral immunity and the prognosis of these patients [14, 20]. The present study demonstrated that both 20S proteasome and the percentage of lymphocyte death values in critically ill patients could be a good predictor for the prognosis in these patients. This study thus hypothesized that the combined monitoring of both 20S proteasome and the percentage of lymphocyte death could be a potent prognostic predictor in critically ill patients.

Conclusions

Elevated serum 20S proteasome in critically ill patients is related to an increased rate of muscle breakdown during their critical illness. Increased lymphocyte apoptosis is a sensitive marker in severe inflammatory states. The correlation between 20S proteasome and the percentage of apoptotic lymphocyte in critically ill patients could be a good predictor of patient outcome, prognosis and survival.

Key messages

  • Critically ill patients, whether septic or non-septic, usually have reduced humoral immunity.

  • Immunologic markers in critically ill septic and non-septic patients are more valuable in predicting prognosis than other biologic markers.

  • The 20S proteasome as a part of proteasome complex is elevated in critically ill patients, whether septic or non-septic, and this elevation is partially due to enhanced and increased cellular damage and partly due to reduced immunity and altered immune response.

  • Increased lymphocyte death is another immunologic prognostic marker occurring in critically ill patients, both septic and non-septic.

  • Joining 20S proteasome and increased lymphocyte death together could have a more prognostic value in predicting survival in these patients than each of them when measured separately.

Abbreviations

7-AAD: 

7-aminoactinomycin D

ELISA: 

enzyme-linked immunosorbent assay

FITC: 

fluorescein isothiocyanate

ICU: 

intensive care unit

PBS: 

phosphate-buffered saline

SOFA: 

Sequential Organ Failure Assessment.

Declarations

Acknowledgements

The authors would like to thank the nursing staff of the ICU of the Emergency Hospital, Tanta University. The authors declare that they did not receive any funds during preparation of this manuscript.

Authors’ Affiliations

(1)
Department of Anesthesia, Tanta University Hospitals
(2)
Department of Clinical Pathology, Tanta University Hospitals

References

  1. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE: Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005, 174: 5110-5118.View ArticlePubMedGoogle Scholar
  2. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE: Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit Care Med 1997, 25: 1298-1307. 10.1097/00003246-199708000-00015View ArticlePubMedGoogle Scholar
  3. Hasselgren PO, Fischer JE: Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 2001, 233: 9-17. 10.1097/00000658-200101000-00003PubMed CentralView ArticlePubMedGoogle Scholar
  4. Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, Fischer JE, Hasselgren PO: Sepsis is associated with increased mRNAs of ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 1997, 99: 163-168. 10.1172/JCI119143PubMed CentralView ArticlePubMedGoogle Scholar
  5. Hershko A, Ciechanover A: The ubiquitin system for protein degradation. Annu Rev Biochem 1992, 61: 761-807. 10.1146/annurev.bi.61.070192.003553View ArticlePubMedGoogle Scholar
  6. Baumeister W, Walz J, Zuhl F, Seemuller E: The proteasome paradigm of a self-compartmentalizing protease. Cell 1998, 92: 367-380. 10.1016/S0092-8674(00)80929-0View ArticlePubMedGoogle Scholar
  7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655. 10.1378/chest.101.6.1644View ArticlePubMedGoogle Scholar
  8. Janssens U, Dujardin R, Graf J, Lepper W, Ortlepp J, Merx M, Zarse M, Reffelmann T, Hanrath P: Value of SOFA (Sequential Organ Failure Assessment) score and total maximum SOFA score in 812 patients with acute cardiovascular disorders. Crit Care 2001, 5: P225. 10.1186/cc1292PubMed CentralView ArticleGoogle Scholar
  9. O'Brien MC, Bolton WE: Comparison of cell viability probes compatible with fixation and permeabilization for combined surface and intracellular staining in flow cytometry. Cytometry 1995, 19: 243-255.View ArticlePubMedGoogle Scholar
  10. Schmid I, Krall WJ, Uittenbogaart CH, Braun J, Giorgi JV: Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunoflurescence in single laser flow cytometry. Cytometry 1992, 13: 204-208. 10.1002/cyto.990130216View ArticlePubMedGoogle Scholar
  11. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis. Flow cytometry detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods 1995, 184: 39-51. 10.1016/0022-1759(95)00072-IView ArticlePubMedGoogle Scholar
  12. Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E, Wolner E, Hoetzenecker K, Boltz-Nitulescu G, Ankersmit HJ: Heightened levels of circulating 20 S proteosome in critically ill patients. Eur J Clin Invest 2005, 35: 399-403. 10.1111/j.1365-2362.2005.01508.xView ArticlePubMedGoogle Scholar
  13. Dutaud D, Aubry L, Henry L, Levieux D, Hendil KB, Kuehn L, Bureau JP, Ouali A: Development and evaluation of a sandwich ELIZA for quantification of the 20 S proteosome in human plasma. J Immunol Methods 2002, 260: 183-193. 10.1016/S0022-1759(01)00555-5View ArticlePubMedGoogle Scholar
  14. Siegel RM, Muppidi J, Roberts M, Porter M, Wu Z: Death receptor signaling and autoimmunity. Immunol Res 2003, 27: 499-512. 10.1385/IR:27:2-3:499View ArticlePubMedGoogle Scholar
  15. Majetscha KM, Perez M, Scorell LT, Lam J, Maldonado ME, Hoffman RW: Circulating 20 S proteosome levels in patients with mixed connective tissue disease and systemic lupus erythematosus. Clin Vaccine Immunol 2008, 15: 1489-1493. 10.1128/CVI.00187-08View ArticleGoogle Scholar
  16. Wada M, Kosaka M, Saito S, Sano T, Tanaka K, Ichihara A: Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med 1993, 121: 215-223.PubMedGoogle Scholar
  17. Bone RC, Newton SI: Sepsis, SIRS, and CARS. Crit Care Med 1996, 24: 1125-1128. 10.1097/00003246-199607000-00010View ArticlePubMedGoogle Scholar
  18. Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, Mouktaroudi M, Plachouras D, Vaki I, Karagianni V, Antonopoulou A, Veloni V, Giamarellou H: Early changes of CD4-positive lymphocytes and NK cells in patients with severe gram-negative sepsis. Crit Care 2006, 10: R166. 10.1186/cc5111PubMed CentralView ArticlePubMedGoogle Scholar
  19. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debré P, Fisher-Hoch SP, McCormick JB, Georges AJ: Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola-virus infected patients. Nat Med 1999, 5: 423-426. 10.1038/7422View ArticlePubMedGoogle Scholar
  20. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, Karl IE: Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999, 96: 14541-14546. 10.1073/pnas.96.25.14541PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Yousef et al.; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.